Non-Current Assets
Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments
Pfizer Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments decreased by 5.9% to $225.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.9%, from $223.00M to $225.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates that the company's private investment portfolio is appreciating in value based on market signals.
Detailed definition
This reflects the cumulative positive adjustments to the carrying value of equity investments that lack a readily determ...
Peer comparison
Specific to companies with venture capital or strategic investment arms.
Metric ID:
equity_securities_no_fv_upward_adjHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $98.00M | $151.00M | $167.00M | $194.00M | $201.00M | $203.00M | $200.00M | $213.00M | $212.00M | $214.00M | $198.00M | $223.00M | $239.00M | $239.00M | $225.00M |
| QoQ Change | — | +54.1% | +10.6% | +16.2% | +3.6% | +1.0% | -1.5% | +6.5% | -0.5% | +0.9% | -7.5% | +12.6% | +7.2% | +0.0% | -5.9% |
| YoY Change | — | — | — | +98.0% | +33.1% | +21.6% | +3.1% | +6.0% | +4.4% | +7.0% | -7.0% | +5.2% | +11.7% | +20.7% | +0.9% |
Range$98.00M – $239.00M
CAGR+26.8%
Avg YoY Growth+17.0%
Median YoY Growth+6.5%
Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments at Other Companies
Frequently Asked Questions
- What is Pfizer's equity securities without readily determinable fair value - cumulative upward adjustments?
- Pfizer (PFE) reported equity securities without readily determinable fair value - cumulative upward adjustments of $225.00M in Q1 2026.
- How has Pfizer's equity securities without readily determinable fair value - cumulative upward adjustments changed year-over-year?
- Pfizer's equity securities without readily determinable fair value - cumulative upward adjustments increased by 0.9% year-over-year, from $223.00M to $225.00M.
- What does equity securities without readily determinable fair value - cumulative upward adjustments mean?
- The total amount of value increases recognized on private equity investments.